40 related articles for article (PubMed ID: 29907544)
1. Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients.
Kandeel EZ; El Sayed G; Elsharkawy N; Eldin DN; Nassar HR; Ibrahiem D; Amin R; Hanafi M; Khalil M; Kamel A
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):541-547. PubMed ID: 29907544
[TBL] [Abstract][Full Text] [Related]
2. FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients.
Rinaldi I; Louisa M; Mulya Sari R; Arwanih E
Onco Targets Ther; 2021; 14():1479-1486. PubMed ID: 33664580
[TBL] [Abstract][Full Text] [Related]
3. [Minimal residual disease level predicts outcomes in the non-favorable risk patients with acute myeloid leukemia].
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):578-585. PubMed ID: 28810324
[No Abstract] [Full Text] [Related]
4. Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia.
Reikvam H; Dillon R
Expert Rev Hematol; 2024; 17(4-5):103-106. PubMed ID: 38654593
[No Abstract] [Full Text] [Related]
5. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.
Heitmann JS; Schlenk RF; Dörfel D; Kayser S; Döhner K; Heuser M; Thol F; Kapp-Schwoerer S; Labrenz J; Edelmann D; Märklin M; Vogel W; Bethge W; Walz JS; Große-Hovest L; Steiner M; Jung G; Salih HR
J Hematol Oncol; 2023 Aug; 16(1):96. PubMed ID: 37587502
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia.
Row C; Lechevalier N; Vial JP; Mimoun A; Bastie JN; Lafon I; Pigneux A; Leguay T; Callanan M; Maynadie M; Béné MC; Dumas PY; Guy J
EJHaem; 2024 Feb; 5(1):84-92. PubMed ID: 38406512
[TBL] [Abstract][Full Text] [Related]
7. Higher mTOR Expression: A Marker of Poor Outcome in Patients with de Novo AML.
Osman N; ELzayat R; ELtounsi I
Indian J Hematol Blood Transfus; 2023 Apr; 39(2):325-329. PubMed ID: 37006968
[TBL] [Abstract][Full Text] [Related]
8. CD117 expression predicted FLT3 mutation in T-cell acute lymphoblastic leukemia.
Wang H; Ni R; Wang A; Liu B
EJHaem; 2024 Feb; 5(1):294-295. PubMed ID: 38406539
[No Abstract] [Full Text] [Related]
9. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
[TBL] [Abstract][Full Text] [Related]
10. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
[TBL] [Abstract][Full Text] [Related]
11. Quizartinib Bests Chemo for
Cancer Discov; 2018 Aug; 8(8):OF2. PubMed ID: 29986851
[TBL] [Abstract][Full Text] [Related]
12. Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib.
Macias RIR; Sánchez-Martín A; Rodríguez-Macías G; Sánchez-Abarca LI; Lozano E; Herraez E; Odero MD; Díez-Martín JL; Marin JJG; Briz O
Oncotarget; 2018 Jun; 9(47):28474-28485. PubMed ID: 29983874
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
[TBL] [Abstract][Full Text] [Related]
14. Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia.
Buccisano F; Dillon R; Freeman SD; Venditti A
Cancers (Basel); 2018 Jun; 10(7):. PubMed ID: 29949858
[TBL] [Abstract][Full Text] [Related]
15. Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors.
Kim C; Kim E
Curr Med Chem; 2019; 26(42):7623-7640. PubMed ID: 29932031
[TBL] [Abstract][Full Text] [Related]
16. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Löwenberg B; Valk PJM
N Engl J Med; 2018 Jun; 378(25):2443. PubMed ID: 29924951
[No Abstract] [Full Text] [Related]
17.
Neuendorff NR; Hemmati P; Arnold R; Ihlow J; Dörken B; Müller-Tidow C; Westermann J
Blood Adv; 2018 Jun; 2(12):1409-1411. PubMed ID: 29914972
[No Abstract] [Full Text] [Related]
18. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.
Vulaj V; Perissinotti AJ; Uebel JR; Nachar VR; Scappaticci GB; Crouch A; Bixby DL; Burke PW; Maillard I; Talpaz M; Marini BL
Leuk Res; 2018 Jul; 70():91-96. PubMed ID: 29908418
[TBL] [Abstract][Full Text] [Related]
19. FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias.
Vela-Ojeda J; Cardenas PV; Garcia-Ruiz Esparza MA; Montiel Cervantes LA; Chavez JG; Caballero AH; Majluf-Cruz A; Vega-López A; Reyes-Maldonado E
Arch Med Res; 2021 Feb; 52(2):217-223. PubMed ID: 33109387
[TBL] [Abstract][Full Text] [Related]
20. How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
Perrone S; Ottone T; Zhdanovskaya N; Molica M
Cancer Drug Resist; 2023; 6(2):223-238. PubMed ID: 37457126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
